Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.

EMBO molecular medicine - 1 Aug 2025

Cho Hyun-Ju, Smith Joy, Switzer Christopher H, Louka Eleni, Charles Rebecca L, Prysyazhna Oleksandra, Schroder Ewald, Fernandez-Caggiano Mariana, de Jesus Daniel Simoes, Eminaga Seda, Yin Xiaoke, Yang Xiaoping, Lynham Steven, Mayr Manuel, Morales Valle, Bianchi Katiuscia, Rajeeve Vinothini, Cutillas Pedro R, Mead Adam J, Eaton Philip

Abstract excerpt

Activating mutations of Src homology-2 domain-containing protein tyrosine phosphatase-2 (Shp2) cause multiple childhood conditions for which there is an unmet therapeutic need, including juvenile myelomonocytic leukemia (JMML) and Noonan syndrome. SFX-01, an α-cyclodextrin-stabilized sulforaphane complex currently in clinical development, covalently adducts cysteine residues. Using unbiased proteomics, its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Leukemia, Myelomonocytic, Juvenile

Share to Mice, Transgenic

Share to Myeloproliferative Disorders

Share to Noonan Syndrome

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Open in PubMed Open full text

Identifiers

PMID: 40640547
DOI: 10.1038/s44321-025-00267-7
PMCID: PMC12340136

Genes

STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.PMID 40640547Read ↗

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.Semantic proximity Read ↗

Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

SHP-2 and myeloid malignancies.Semantic proximity Read ↗

Shp2 function in hematopoietic stem cell biology and leukemogenesisSemantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defectsSemantic proximity Read ↗

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).Semantic proximity Read ↗

The Landscape of Protein Tyrosine Phosphatase (Shp2) and CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.